HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: clinchem.2005.065995v1 52/7/1423    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (3) Citing Articles via Google Scholar Google Scholar Articles by Moriyama, M. Articles by Kumagai, S. Search for Related Content PubMed PubMed Citation Articles by Moriyama, M. Articles by Kumagai, S. Related Collections Clinical Immunology

Performance Evaluation and Cross-Reactivity from Insulin Analogs with the ARCHITECT Insulin Assay,

¹ Department of Clinical Laboratory, Kobe University Hospital, Kobe, Hyogo, Japan; ² Department of Clinical Pathology and Immunology, Kobe University Graduate School of Medicine, Kobe, Hyogo, Japan;

^aaddress correspondence to this author at: Department of Clinical Pathology and Immunology, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-cho, Chuo-ku, Kobe, Hyogo 650-0017, Japan; fax 81-78-382-6209, e-mail kumagais{at}kobe-u.ac.jp

Abstract

Background: Insulin measurement is used for the diagnosis of hypoglycemia and for insulin pharmacokinetic evaluations. We assessed the analytical and clinical performance of the ARCHITECT® insulin assay, a chemiluminescent immunoassay recently introduced for the ARCHITECT i2000 fully automated immunoassay analyzer (Abbott Laboratories). We also tested whether major insulin analogs cross-reacted with the immunoassay reagents.

Methods: We used Clinical and Laboratory Standards Institute protocols to assess the analytical performance of the ARCHITECT insulin assay and compared its accuracy with that of the E-test TOSOH II (IRI) from TOSOH Corporation. We used 3 recombinant insulin analogs (lispro, aspart, and glargine) to evaluate the cross-reactivity of insulin analogs with the ARCHITECT immunoassay reagent.

Results: The total CV for the ARCHITECT assay was <5%. Correlation between the ARCHITECT insulin assay and the E-test TOSOH II (IRI) was satisfactory in the measured range, but we detected a slope deviation between the assays. The ARCHITECT insulin assay showed low cross-reactivity to the insulin analog aspart, whereas it detected the other insulin analogs, lispro and glargine, in concentrations as high as the theoretical concentrations.

Conclusions: The ARCHITECT insulin assay showed favorable basic performance, including reproducibility, dilution linearity, detection limit, and effects of interfering substances. When interpreting results, clinicians and laboratory pathologists should be aware of the cross-reactivity of the ARCHITECT and other immunoassays to specific insulin analogs prescribed to diabetes patients.

The following articles in journals at HighWire Press have cited this article:

				T. Linn, B. Fischer, N. Soydan, M. Eckhard, J. Ehl, C. Kunz, and R. G. Bretzel Nocturnal Glucose Metabolism after Bedtime Injection of Insulin Glargine or Neutral Protamine Hagedorn Insulin in Patients with Type 2 Diabetes J. Clin. Endocrinol. Metab., October 1, 2008; 93(10): 3839 - 3846. [Abstract] [Full Text] [PDF]

				S. E. Manley, I. M. Stratton, P. M. Clark, and S. D. Luzio Comparison of 11 Human Insulin Assays: Implications for Clinical Investigation and Research Clin. Chem., May 1, 2007; 53(5): 922 - 932. [Abstract] [Full Text] [PDF]